Nama's AI scorecard currently rates PTC Therapeutics Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does PTCT report earnings?

PTC Therapeutics's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.14.

What is the PTCT price target?

The median analyst price target from 15 analysts is $98.00, with a range of $62.00 – $137.00.

Is PTCT Shariah compliant?

Nama's AAOIFI-style screen reads PTC Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

PTC Therapeutics (PTCT)

Healthcare · Biotechnology · NASDAQ

PTC Therapeutics (PTCT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $5.47B and a free-cash-flow yield of 7.9%. Over the most recent reported fiscal year, revenue grew 114.5%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -12.9% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-28.0%

How far the last close sits under the highest price of the past five years.

Market cap	$5.47B
Trailing P/E	—
Price / book	—
Price / sales	4.7
FCF yield	7.9%
Dividend yield	—
Gross margin	93.0%
Operating margin	11.6%
Net margin	-3.8%
Revenue growth (YoY)	+114.5%
Revenue growth (3-yr annual)	+35.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

PTCT earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate $0.14). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$0.39	$0.27	-244.4%	$357.81M
Q2 2026	Jul 30, 2026	$0.92	$0.34	+170.6%	$360.52M
Q1 2026	May 7, 2026	-$0.03	-$0.44	+93.2%	$272.55M
Q4 2025	Feb 19, 2026	-$1.80	-$0.40	-350.0%	$164.68M

PTCT analyst price target

Median target $98.00 from 15 analysts, ranging $62.00 – $137.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live PTCT data on Nama Insights →

PTCT FAQ

Is PTCT a buy?: Nama's AI scorecard currently rates PTC Therapeutics Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PTCT report earnings?: PTC Therapeutics's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.14.
What is the PTCT price target?: The median analyst price target from 15 analysts is $98.00, with a range of $62.00 – $137.00.
Is PTCT Shariah compliant?: Nama's AAOIFI-style screen reads PTC Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.